Literature DB >> 16413612

Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia.

Takahiro Shinkai1, Daniel J Müller, Vincenzo De Luca, Sajid Shaikh, Chima Matsumoto, Rudi Hwang, Nicole King, Joseph Trakalo, Natalia Potapova, Gwyneth Zai, Hiroko Hori, Osamu Ohmori, Herbert Y Meltzer, Jun Nakamura, James L Kennedy.   

Abstract

A possible involvement of oxidative stress in the pathophysiology of tardive dyskinesia (TD) has previously been proposed (reviewed in [Andreassen, O.A., Jorgensen, H.A., 2000. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Progress in Neurobiology 61, 525-541.]). Long-term administration of neuroleptics alters dopaminergic turnover, which results in increased formation of reactive oxygen species (ROS). This is hypothesized to lead to TD through neuronal toxicity as a consequence of oxidative stress. In the present study, the relationship between TD and a possible functional polymorphism of the human glutathione peroxidase (GPX1) gene (an important antioxidant enzyme) was studied in 68 chronic treatment-refractory patients with schizophrenia. A proline (Pro) to leucine (Leu) substitution at codon 197 (Pro197Leu) in the GPX1 gene was genotyped. No significant difference in total Abnormal Involuntary Movements Scale (AIMS) scores was observed among patients in the three genotype groups. Moreover, no significant differences in genotype or allele frequencies were observed between subjects with and without TD. Our results suggest that the GPX1 gene polymorphism does not confer increased susceptibility to TD, although further studies are warranted before a conclusion can be drawn.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413612     DOI: 10.1016/j.psychres.2004.06.023

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

2.  BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Authors:  Itaru Miura; Jian-Ping Zhang; Masahiro Nitta; Todd Lencz; John M Kane; Anil K Malhotra; Hirooki Yabe; Christoph U Correll
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

Review 3.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Gene polymorphisms against DNA damage induced by hydrogen peroxide in leukocytes of healthy humans through comet assay: a quasi-experimental study.

Authors:  Ana L Miranda-Vilela; Penha Cz Alves; Arthur K Akimoto; Graciana S Lordelo; Carlos A Gonçalves; Cesar K Grisolia; Maria N Klautau-Guimarães
Journal:  Environ Health       Date:  2010-05-05       Impact factor: 5.984

5.  Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Marko Saje; Katja Goričar; Vita Dolžan; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Neurochem Res       Date:  2012-12-02       Impact factor: 3.996

6.  Analysis of manganese superoxide dismutase (MnSOD: Ala-9Val) and glutathione peroxidase (GSH-Px: Pro 197 Leu) gene polymorphisms in mood disorders.

Authors:  Birgül Elbozan Cumurcu; Huseyin Ozyurt; Omer Ates; Isil Gogcegoz Gul; Suleyman Demir; Rifat Karlıdag
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

7.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 8.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

9.  Effects of GSTA1 and GPX3 Polymorphisms on the Risk of Schizophrenia in Chinese Han Population.

Authors:  Chao Liu; Sijia Song; Junkai Zhang; Xiao Li; Huijie Gao
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-09       Impact factor: 2.570

Review 10.  Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Authors:  Mujeeb U Shad
Journal:  Behav Sci (Basel)       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.